Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Macrogenics (MGNX)

Macrogenics (MGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 184,312
  • Shares Outstanding, K 63,556
  • Annual Sales, $ 149,500 K
  • Annual Income, $ -74,620 K
  • EBIT $ -73 M
  • EBITDA $ -67 M
  • 60-Month Beta 1.45
  • Price/Sales 1.27
  • Price/Cash Flow N/A
  • Price/Book 3.50

Options Overview Details

View History
  • Implied Volatility 137.80% (+22.87%)
  • Historical Volatility 121.42%
  • IV Percentile 23%
  • IV Rank 16.01%
  • IV High 704.13% on 04/03/25
  • IV Low 29.83% on 04/04/25
  • Expected Move (DTE 28) 0.79 (27.26%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 167
  • Volume Avg (30-Day) 242
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 3,025
  • Open Int (30-Day) 2,437
  • Expected Range 2.11 to 3.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.55
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.75
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.60 +81.82%
on 02/24/26
3.54 -18.08%
on 03/11/26
+1.17 (+67.63%)
since 02/19/26
3-Month
1.50 +93.33%
on 12/22/25
3.54 -18.08%
on 03/11/26
+1.40 (+93.33%)
since 12/19/25
52-Week
0.99 +192.93%
on 04/07/25
3.54 -18.08%
on 03/11/26
+0.72 (+33.03%)
since 03/19/25

Most Recent Stories

More News
MacroGenics: Q4 Earnings Snapshot

MacroGenics: Q4 Earnings Snapshot

MGNX : 2.90 (-2.68%)
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for...

MGNX : 2.90 (-2.68%)
MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 2.90 (-2.68%)
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment...

MGNX : 2.90 (-2.68%)
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 2.90 (-2.68%)
MacroGenics: Q3 Earnings Snapshot

MacroGenics: Q3 Earnings Snapshot

MGNX : 2.90 (-2.68%)
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platform...

MGNX : 2.90 (-2.68%)
MacroGenics to Participate in the Stifel 2025 Healthcare Conference

ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 2.90 (-2.68%)
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 2.90 (-2.68%)
Cancer Treatment Revolution Drives $903B Market as New Therapies Gain Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Researchers at Moffitt Cancer Center have uncovered a promising new therapeutic strategy that could potentially...

ONCY : 0.9789 (+1.92%)
BCT.TO : 6.19 (+4.56%)
MGNX : 2.90 (-2.68%)
KPTI : 7.73 (-7.98%)
BCTX : 4.52 (+4.87%)
CTOR : 0.6908 (+1.29%)

Business Summary

MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics...

See More

Key Turning Points

3rd Resistance Point 3.14
2nd Resistance Point 3.06
1st Resistance Point 2.98
Last Price 2.90
1st Support Level 2.82
2nd Support Level 2.73
3rd Support Level 2.65

See More

52-Week High 3.54
Last Price 2.90
Fibonacci 61.8% 2.57
Fibonacci 50% 2.26
Fibonacci 38.2% 1.96
52-Week Low 0.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar